Newswire (Published: Friday, April 7, 2017, Received: Thursday, March 30, 2017, 10:29:42 PM CDT)

Word Count: 511

Researchers from University of Toronto Detail Findings in Prostate Cancer (Effects of Long-Term Androgen Deprivation Therapy on Cognitive Function Over 36 Months in Men With Prostate Cancer)

By a News Reporter-Staff News Editor at Drug Week -- Fresh data on Oncology - Prostate Cancer are presented in a new report. According to news reporting from Toronto, Canada, by NewsRx journalists, research stated, "Many men with prostate cancer (PC) require long-term androgen deprivation therapy (ADT), but to the authors' knowledge, its effects on cognitive function beyond 1 year are not described. Three groups of men aged >= 50 years who were matched based on age and education were enrolled: 77 patients with nonmetastatic PC who initiated continuous ADT, 82 patients with PC who were not receiving ADT (PC controls), and 82 healthy controls."

The news correspondents obtained a quote from the research from the University of Toronto, "A battery of 14 neuropsychological tests, examining 8 cognitive domains, was administered on 5 occasions over 36 months. Changes in cognitive scores over time were analyzed using 3 approaches: linear mixed effects regression, the percentage of participants per group with declines in >= 1/2 cognitive tests, and a global summary of cognitive change. The mean age of the study subjects was 68.9 years, with a median of 16 years of education. In mixed effects models adjusted for age and education, ADT use was not found to be associated with significant changes over time in any cognitive test compared with healthy controls. The percentage of participants declining by >= 1.5 standard deviations in >= 2 tests or >= 2 standard deviations in >= 1 tests was similar across groups. A global summary of cognitive change found no statistically significant worsening of cognitive function among ADT users compared with controls. Sensitivity analyses adjusting for duration of ADT and using multiple imputation for missing data did not materially alter the study findings."

According to the news reporters, the research concluded: "The ongoing use of ADT for up to 36 months does not appear to be associated with cognitive decline."

For more information on this research see: Effects of Long-Term Androgen Deprivation Therapy on Cognitive Function Over 36 Months in Men With Prostate Cancer. Cancer, 2017;123(2):237-244. Cancer can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Cancer - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0142)

Our news journalists report that additional information may be obtained by contacting S.M.H. Alibhai, University of Toronto, Inst Med Sci, Toronto, ON, Canada. Additional authors for this research include N. Timilshina, S. Duff-Canning, H. Breunis, I.F. Tannock, G. Naglie, N.E. Fleshner, M.D. Krahn, P. Warde, S. Marzouk and G.A. Tomlinson (see also Oncology - Prostate Cancer).

Keywords for this news article include: Toronto, Ontario, Canada, North and Central America, Therapy, Diagnostics and Screening, Drugs and Therapies, Prostatic Neoplasms, Prostate Cancer, Androgens, Oncology, University of Toronto.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Central America
North America
Canada
Americas
Ontario
Toronto

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer